Therapy

Why?

• It improves lung perfusion and ventricular wall movement, but there is no clear effect on mortality or recurrent PE. ^d  
• The risk of bleeding is increased ^a
• No thrombolytic has been shown to better than another. ^d

Thrombolysis increases the risk of bleeding

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNH (95% CI)
pulmonary embolism a	urokinase	heparin	bleeding at 14 days	45%	-68% (-160% to -8%)	5 (3 to 28)
			severe bleeding at 14 days	26%	-90% (-270% to 1%)	8 (4 to 240)